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Tubulopathy is a heterogeneous group of diseases combined by the nephron functions disorders of one or more 
enzyme proteins in the tubular epithelium that cease to function as a reabsorption of one or several substances filtered 
from the blood through the glomeruli into tubules, which determines the development of the disease. This review 
addresses the tubulopathies accompanying bone disease, namely: de Tony-Debre-Fanconi syndrome (autosomal 
dominant, autosomal recessive, X-linked), renal distal metabolic acidosis type I (classic, autosomal dominant, 
autosomal recessive inheritance), renal distal tubular metabolic acidosis I (autosomal dominant,  autosomal recessive 
inheritance) and type II (autosomal recessive inheritance accompanying delayed mental development and eye 
disorders), combined distal and proximal renal tubular metabolic acidosis type III (autosomal recessive inheritance 
characterized by osteoporosis), hypophosphatemia rickets (X-linked dominant, autosomal dominant, primary 
hypercalciuria, autosomal recessive inheritance). However, the diagnosis of tubulopathy remains complex and requires 
expensive laboratory equipment and specialist expertise; it can be diagnosed in children showing the following 
symptoms: impaired growth, vitamin D resistant rickets (lower limb deformities between 2 and 3 years of age). In the 
evaluation of such patients urine analysis is commonly used (levels of calcium, phosphorus, pH, bicarbonate, sodium, 
potassium, glucose, creatinine, protein, amino acids), blood count (levels of creatinine, uric acid, alkaline phosphatase, 
glucose, pH and sodium, bicarbonate, potassium, chloride, calcium, phosphorus ions), ultrasound of the kidneys to 
detect nephrocalcinosis. Determination of serum parathyroid hormone concentration, vitamin D metabolites, 
aldosterone and plasma renin activity, cysteine lymphocyte concentration (suspicion to diagnose cystinosis) and 
ophthalmologist examination may also be used as additional diagnostic methods. Despite the fact that most 
tubulopathies can be diagnosed clinically, molecular genetic studies are needed to clarify the type of inheritance and 
prognosis. The use of calcitriol will help in the management of phosphorous levels in the blood. Correction of vitamin 
D deficiency state is not required. Calcitriol supplementation may prevent secondary hyperparathyroidism resulting 
from increased phosphate intake.  
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Introduction  
 
Tubulopathies form a heterogeneous group of diseases combined 
by the presence of disorders in the tubular epithelium of the nephron 
functions of one or more enzyme proteins that cease to function as 
reabsorption of one or several substances filtered from the blood 
through the glomeruli into tubules, which determines the development 
of the disease. By origin they are classified into primary and secondary 
tubulopathies. The primary ones involve a hereditary defect of the genes 
that regulate the function of a particular tubular enzyme, resulting in the 
development of pathology usually from the first months or years of life 
of the child. Currently, not all genes are known, the mutation of which 
leads to the development of hereditary tubulopathies.  
Based on the etiology, primary tubulopathy is divided into proximal 
(different forms of Fanconi syndrome, glycineuria, cystonuria, phos-
phate diabetes, renal tubular acidosis type II (in children), renal glucose-
uria, etc.), distal (renal tubular acidosis type I, nephrogenic diabetes 
insipidus, pseudogiopoaldosteronism) and mixed, and by the number of 
disturbed functions, such as isolated (monosymptomatic) and combined 
(polysymptomatic).  
For a practical physician a classification based on the isolation of 
the leading clinical symptom complex is considered optimal. At present, 
more than 30 different primary tubulopathies are known, their number 
increases with further study of the pathophysiology of the kidneys. 
According to some authors, it is advisable to classify tubulopathies 
according to the leading clinical manifestation. The classification below 
does not purport to represent all existing hereditary tubulopathies and is 
limited to the most common diseases.  
According to the main syndromes, tubulopathies can be divided 
into three groups:  
1. Tubulopathies accompanying bone diseases (primary de Tоni-
Debre-Fanconi syndrome (autosomal dominant, autosomal recessive, 
X-linked), renal distal metabolic acidosis type I (classic, autosomal do-
minant, autosomal recessive inheritance), renal distal tubular metabolic 
acidosis I (autosomal dominant, autosomal recessive inheritance) and 
type II (autosomal recessive inheritance accompanied by delayed 
mental development and eye disorders), combined distal and proximal 
renal tubular metabolic acidosis type III (autosomal recessive inheri-
tance characterized by osteoporosis), hypophosphatemia rickets (X-
linked dominant, autosomal dominant, primary hypercalciuria, autoso-
mal recessive inheritance).  
2. Hereditary tubulopathies accompanying polyuria (renal glycos-
uria, nephrogenic diabetes insipidus, pseudo hyperaldosteronism).  
3. Hereditary tubulopathies characterized by nephrolithiasis (cystin-
uria, glycosuria, primary hyperoxaluria, xanithinuria, alkapthonuria, 
Dent disease).  
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We provide a brief overview of the tubulopathies associated with 
bone disease.  
 
Primary de Tоni-Debre-Fanconi syndrome (ОМІМ 134600, 
613388, 615605, 616026)  
 
Syn.: Fanconi syndrome, glucoaminophosphate diabetes, glucose-
phamide diabetes, rickets hereditary vitamin D-resistant, idiopathic Fan-
coni syndrome, Fanconi hereditary syndrome, Renal Fanconi syndrome, 
Fanconi syndrome, Primary de Toni-Debre-Fanconi syndrome, Inheri-
ted Fanconi syndrome.  
Fanconi syndrome is divided into four types: type I (OMIM 
134600), type II (OMIM 613388), type III (OMIM 615605), type IV 
diabetes with MODY (OMIM 616026).  
In its complete form, Fanconi syndrome (disease) is characterized 
by a triad of symptoms: hypophosphatemia associated with bone disease, 
excessive renal wasting of glucose and amino acids, arising as a result of 
violations in the proximal segment of the nephron (Bacconi et al., 2005).  
Is associated with the most severe types of prolapsed tubulopathies. 
The disease is genetically predisposed (Bai et al., 2004; White et al., 2005).  
Among other researchers, a Swiss pediatrician Fanconi was the first 
to describe the particular signs of the disease. In 1931, he described a 
child with dwarfism, rickets, glycosuria and albuminuria. Two years 
later, de Toni found hypophosphatemia to be further clinical evidence 
and, later on, Debré determined elevated levels of organic acids in urine, 
called aminoaciduria (Younes et al., 2003; Zivičnjak et al., 2011). 
Aetiopathogenesis 
It is believed that the genetically determined defects of enzymatic 
phosphorylation in the renal tubules (combined tubulopathy); deficiency 
of enzymes from the complexes II and III (succinate dehydrogenase and 
cytochrome oxidase) of the respiratory chain are the basis of the disease. 
Some authors believe that the basis of the disease is mitochondrial 
genesis (Lichter-Konecki et al., 2001; Watanabe, 2017).  
These mutations lead to various defects in the renal proximal tubu-
les leading to excessive urinary waste of phosphates, glucose and amino 
acids, as well as to the acid-base imbalance. Metabolic acidosis and in-
sufficiency of phosphorus compounds can also contribute to bone de-
formities (osteomalacia (adults) and rickets (children)) (Pishak et al., 2015).  
Based on its etiology, the syndrome can be divided into two main 
categories: primary (hereditary) and secondary (acquired). The second-
dary one is the most common.  
The primary (hereditary) syndrome resulting from a genetic mutati-
on occurs in approximately 1 in 20.000 births, de Tony-Debre-Fanconi 
disease occurs in approximately 1 in 40.000 births. This disease is 
believed to be caused by the damage to the transport systems in the 
proximal tubules resulting in disruption of phosphate, glucose and 
amino acids transportation. Typical episodic features include dehydra-
tion, symptoms of rickets and delayed growth. Sometimes the disorder 
manifests itself at an older age as a renal failure (Tasic, 2008; Besouw 
et al., 2017). Damage to the sodium transport systems in the proximal 
tubules (for example, in acute renal failure) leads to a pronounced 
sodium reabsorption and tubular acidosis disorder, hydrogen ion 
transport and proximal tubules reabsorbed substances can be disrupted: 
glucose, phosphate, uric acid, amino acids.  
An acquired Fanconi syndrome develops associated with other 
hereditary disorders or kidney diseases, namely: congenital metabolism 
or transport disorders (cystitis, tyrosineemia type I, glycogenosis type 
XI, galactosemia, congenital intolerance to fructose, Wilson disease, 
oculocerebrorenal syndrome (Lowe syndrome), vitamin D-resistant 
rickets, impaired energy metabolism, McArdle-Schmid-Pearson disease, 
cytochrome C oxidase deficiency (COX deficiency), pyruvate carboxy-
lase (PC) deficiency, carnitine palmitoyltransferase I (CPT I) deficien-
cy); chronic diseases (paraproteinemia (multiple myeloma), tubulointes-
titial nephropathies, nephrotic syndrome, nephropathy in renal trans-
plant allografts, malignant tumors (paraneoplastic disease)); heavy me-
tal salts intoxication (mercury, lead, cadmium, uranium); organophos-
phate poisoning (toluene, maleic acid, lysol); drug-induced toxicity (pla-
tinum-based agents, expired tetracycline and gentamicin), severe burns. 
The syndrome may be complete if these three symptoms (glycosuria, 
phosphaturia and aminoaciduria) are observed and incomplete if there 
are only two of them: 
– glycosophosphamide diabetes without acidosis (described by 
Dent and Kyle);  
– phosphoglucide diabetes (described by Mac Cune);  
– aminophosphoric diabetes (described by Jonxin, Wallgren and Nicola);  
– glucosamine diabetes (described by Juillard and Fischer).  
Clinical evidence 
The severity of clinical manifestations and metabolic disorders may 
differ depending on two clinical and biochemical variants of the disease: 
in children (early) and adults (late). The pediatric form arises during the 
1st year of life and manifestations can include frequent vomiting, loss of 
appetite, mental and physical developmental delay, a tendency to severe 
infectious diseases. Gradually there is a proportional dwarfism, rickets 
and renal insufficiency.  
Early dwarfism: intense increase in the rate of growth in height and 
weight (up to 30%) that occurs during the 5–6 of normal growth and 
weight gain.  
Median age at diagnosis of rickets is 10–12 months; it is characteri-
zed by a topographical specificity: the skull is deformed by localized 
impact; in contrast to fractures in the thoracic (mid back) spine and 
limbs. Bone pain of moderate intensity primarily tends to be localized in 
the limbs and spine. It is associated with severe hypocalcaemia (1.6–
1.8 mmol/L) and reduced intestinal calcium absorption.  
Polydipsia and polyuria are common for the beginning of the 
disease, progressively intensifying and systematically regressing at 
different age periods, but never go away completely.  
General symptoms of chronic inflammatory myopathy include 
slow but progressive muscle weakness and transverse abdominal dis-
ruption. It is marked by frequent constipation.  
Eye disorders: pigment retinitis, congenital cataracts. Renal failure 
progresses into a chronic kidney disease between 8–14 years.  
The late syndrome is generally noticed between 3 and 6 years of 
age; it is accompanied by the delayed changes in general medical 
condition, osteomalacia augmentation and hypokalemic paralysis. 
Characterized by polyuria and polydipsia, moderate developmental 
delay, severe genu valgum deformities; low level of phosphate, 
potassium and calcium in the blood, normal amino acids and glucose 
concentration. Low plasma bicarbonate concentration is common in the 
early stages of the disease, later on hyperchloremic acidosis develops. It 
is characterized by disturbances in the concentration of renal function 
(hipostenuria, polyuria), sometimes moderate proteinuria, generalized 
hyperaminociduria, elevated excretion of phosphates, calcium, glucose, 
citrates in patients. Urine reaction is neutral or alkaline (Lichter-Konecki 
et al., 2001; Tasic et al., 2008; Watanabe, 2017).  
In patients with de Toni-Debre-Fanconi syndrome the following 
laboratory abnormalities:  
– hypophosphatemia;  
– hypocalcemia;  
– hypokalemia;  
– hyponatremia;  
– elevated alkaline serum phosphatase;  
– metabolic acidosis (pH: 7.25–7.35; base excess BE (elevated 
level of alkalinity): –12– –10 mmol/L) secondary to reduced proximal 
tubular reabsorption of bicarbonate:  
– increased Pyruvic and Lactic Acid Content of Blood;  
– hypophosphaturia;  
– calciuria;  
– polyuria;  
– decreased serum uric acid with an increased uric acid clearance;  
– glycosuria (above 20–30 g/L);  
– development of generalized hyperaminociduria (less than 2.0–
2.5 g/24 h) in all the amino acid types;  
– failure of amino acid genesis – reduce titratable acidity;  
– increased urine pH (higher than 6.0);  
– tubulin-like proteinuria - the presence of immunoglobulins in the 
urine of the light chains, lysozyme, β2-microglobulin.  
Radiological method features has proven to be useful in detecting 
pronounced osteoporosis with severe disorders in metaphyseal areas 
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with characteristic bowing of the bones, accompanied by a delayed 
bone age relative to chronological age of a child.  
Additionally, type II is characterized by increased serum 25-hydro-
xyvitamin D levels in children  and decreased – in adults (Levtchenko 
et al., 2006; Magen et al., 2010). In type III, varus angulation of the lower 
extremities, while renal failure does not occur (Klootwijk et al., 2014). 
Type IV could be suspected in infants who are large for their gestational 
age (more than 4 kg), subject to neonatal hypoglycemia, hyperinsuli-
nism and hepatomegaly. There is a risk of development of insulin depen-
dent diabetes mellitus (maturity-onset diabetes of the young (MODY)) 
accompanied by nephrocalcinosis and renal failure (Hamilton et al., 2014).  
Treatment  
Dietary restrictions:  
– in galactosemia: milk;  
– in fructose intolerance: sugar, honey, apples, pears, watermelons, 
carrots;  
– in cystonesis: protein foods, high-methionine foods, kitchen salt;  
– in tyrosinemia: high-tyrosine and methionine foods;  
Recommended foods (Novikov et al., 2004; Savenkova and 
Leviashvili, 2004):  
– in pyruvate carboxylase deficiency: low carb high fat diet (LCHF diet);  
– potassium-, calcium-, phosphorus-rich foods;  
– liquid intake is typically not restricted.  
Correction for renal tubular metabolic acidosis: 
– 2% or 4% sodium bicarbonate solution (5 ml/kg/day) in 4 divided 
doses (intravenous, oral, rectal administration) and calcium supplements; 
– citrate mixture to reduce the dose of sodium bicarbonate;  
– treatment of hypokalaemia (potassium supplements);  
Correction for hypophosphatemic rickets with normal calcium level 
and/or hypocalcemia, osteoporosis:  
– calcium supplements (calcium carbonate, calcium phosphate, calci-
um citrate, calcium glycerophosphate). Phosphate buffer (continuously); 
Active metabolites of vitamin D: oxide; calcidiol; calcitriol; or 
calcium-, phosphorus- and calcitriol- containing binding agents. 
Recombinant human growth hormone treated with 0.6–0.7 IU/kg/ 
week of rhGH administered daily for 3 months.  
 
Renal tubular acidosis (RTA) 
 
Several bone deformities in children with tubulopathies are associa-
ted with a number of factors; metabolic acidosis should be considered a 
sign of an underlying disease process. The most vital parameter affec-
ting protein binding of calcium is the pH. Since bone responds to over-
acidity, chronic metabolic acidosis of any origin can cause growth 
retardation. In addition, metabolic acidosis causes alterations in the bone 
reabsorptive capacity for calcium and therefore increases urinary calci-
um excretion. The development of metabolic acidosis is caused by a 
violation of reabsorption of bicarbonates and secretion of hydrogen 
ions, as well as a violation of the activity of carbonic anhydrase with 
respect to hydration of СО2 (this enzyme also stimulates proton secreti-
on not only in renal proximal tubules and collecting ducts, but also in 
osteoclasts) (Kartamyisheva et al., 2011).  
The disease is inherited by both auto dominant and auto recurrent 
types; and is clinically characterized by hyperchloremic acidosis and 
baseline deficiency in the serum.  
There are two types of disease: distal renal tubular acidosis (dRTA) 
type I is characterized by an impairment of the normal urinary acidify-
cation process in the distal part of the nephron; Proximal renal tubular 
acidosis (pRTA) type II is characterized by a defect in the ability to 
reabsorb bicarbonates in the proximal tubule. Type III is a combination 
of isolated proximal (type 2) or distal (type 1) tubular pathologies.  
Type I dRTA  
There are distinguished two types of the disease by the pattern of 
inheritance: autosomal dominant or autosomal recessive. 
Classical type I dRTA autosomal dominant (ОМІМ 179800) 
The syndrome is caused by mutations in the SLC4A1 (МІМ 
109270) gene, found in a place on the long arm of chromosome 17 
called 17q21.31 (Bergwitz et al., 2006). Clinically it is characterized by 
osteomalacia, plastic deformity of the long tubular bones and growth 
retardation. It is caused by the disorder of the tubular acidogenesis, 
when the kidneys fail to reduce the urine pH associated with the 
increase in hydrogen ion concentration as a result of the increased 
reverse diffusion of hydrogen ions through the tight junctions that hold 
the tubular epithelial cells. The distal canal is unable to create a 
concentration gradient between the tubular fluid and the blood. This 
finding suggests that bicarbonate ions have been effectively replaced by 
chloride ions and the hyperchloremic metabolic acidosis arises (Fry & 
Karet, 2007; Kraut et al., 2010).  
First, in people with this syndrome in their teens or adulthood  the 
following signs and symptoms are observed : poor appetite, polyuria, 
polydipsia, rapid fatigability and delayed physical development. Next 
bone deformities commonly associated with rickets (lower-limb valgus 
deformity, "rachitic rosary", widening of wrist, frontal and parietal 
lobe), as well as with the pronounced muscular hypotonia. The first 
manifestations of the renal tubular acidosis usually appear in children 
two years of age. People with more severe and prolonged rickets may 
experience permanent bone deformities (Rodriguez, 2002; Karet, 2002; 
Civitelli & Ziambaras, 2011).  
Laboratory studies have revealed metabolic acidosis, low plasma bi-
carbonate- and increased plasma chloride concentration, hypocalcemia, 
hypokalemia, hypophosphatemia, increased alkaline phosphatase activi-
ty, secondary hyperparathyroidism and decreased intestinal calcium ab-
sorption. High-resolution ultrasound has been found to be a sensitive 
and reliable method for the detection of nephrocalcinosis. A significant-
ly decreased renal function (urine specific gravity from 1001 to1008) is 
observed, a persistently low urine pH (<5.5), as well as normal bicarbo-
nate levels. Hypercalciuria is associated with excessive urinary calcium 
excretion (as a compensation for a metabolic acidosis) (Bergwitz & 
Jüppner, 2010; Escobar et al., 2013) mediated by the renal Ca2+ tran-
sport proteins (Laing & Unwin, 2006; Nijenhuis et al., 2006) and in-
creased renal sodium reabsorption. This association may implicate increa-
sed renal blood flow as a contributory cause of urinary hyperexcretion 
of insoluble mineral salts, which can lead to recurrent kidney stones or 
nephrocalcinosis. These factors, together with high urine pH, contribute 
to abnormal accumulation of calcium and the development of 
nephrocalcinosis and / or renal stones, which may lead to further 
deterioration of renal function (Karet, 2002; Loymana et al., 2010).  
Type I autosomal recessive dRTA with deafness or with preserved 
hearing (ОМІМ 602722) Syn.: RTADR.  
Defects in the ATP6V0A4 (7q34) or ATP6V1B1 (2р13.3) genes 
cause autosomal recessive dRTA with deafness and with preserved 
hearing, respectively. However, several patients with ATP6V0A4 
mutations have developed hearing loss, usually in young adulthood.  
Clinical features. This syndrome occurs in early childhood associa-
ted with frequent vomiting and development of dehydration followed 
by growth retardation and nephrocalcinosis, preceded by chronic renal 
insufficiency. Often the syndrome is associated with the development of 
neurosensory deafness. Laboratory findings are the same as in the 
autosomal dominant form. Parents are usually married (Leung, 2014). 
Type II proximal renal tubular acidosis with ocular abnormalities 
and mental retardation (ОМІМ 604278) 
The syndrome is caused by the function mutations in the SLC4A4 gene 
(MIM 603345) located on chromosome 4 (4q13.3) (Igarashi et al., 2001).  
It is associated with the immature nephrons, low carbonic 
anhydrase II(c) and I(b) activity; as well as low HCO3- ATPase activity 
in mitochondria of renal tubular cells. 
Clinical features. Reduced proximal tubular reabsorption of 
bicarbonate, resulting in impaired capacity for net acid excretion and 
persistent hyperchloremic metabolic acidosis. In the first few months of 
life a history of vomiting, thirst, subfebrile temperature, marked delay in 
physical growth, rickets-like changes in the skeleton may be present. 
Developmental delay, nystagmus, congenital cataracts, corneal stromal 
opacities, glaucoma and permanent enamel hypoplasia (Pettifor, 2008). 
Laboratory diagnosis: increased osmotic fragility of erythrocytes 
with slightly acid urine (pH less than 6). Hydrogen ions (H+) excretion 
remains within normal limits and corresponds to nutrition. The bicarbo-
nate threshold for bicarbonate reabsorption is decreased, while its 
excretion is sharply increased. 
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Treatment: Dietary restriction of oxalate intake (sorrel, spinach, 
tomato juice, chocolate, etc.), alkaline mineral water, administration of 
sodium bicarbonate to restore normal acid base status; or diluted citrate 
solution (Shohla solution) at a dose 5–30 mmol HCO3–/kg/day. Adding 
more potassium is typically needed. Shohla solution (pharmacy – prepa-
red) containing in 1000 mL not less than 140 g of citric acid and 90 g of 
sodium citrate (1 g of NaHCO3 = 12 mg of alkalosis, 10 ml of Shohla 
solution = 10 mg of alkalosis). Vitamin D treatment in patients with 
osteoporosis and osteomalacia.  
Combined proximal and distal renal tubular acidosis (Type III 
RTA) (Autosomal recessive inheritance associated with osteoporosis) 
(ОМІМ 267200) 
The syndrome is almost invariably associated with increased 
bicarbonate excretion.  
Clinical features. Metabolic acidosis in early infancy associated with 
hypokalemic paralysis, osteomalacia with subsequent skeletal deformi-
ties and growth retardation and early osteoporosis.  
Radiographic evaluation of nephrocalcinosis, abdominal calcificati-
ons, osteoporosis and bone deformation. Autosomal recessive inheri-
tance, much more prevalent in males.  
 
Hypophosphatemic rickets (hypophosphatemia)  
 
The maintenance of normal phosphate homeostasis constitutes the 
basic physiologic function of the kidneys (Bastepe & Jüpper, 2008; 
Natochin, 2008). Serum phosphate concentration exists in three major 
forms: free ionized (84–85%), protein-bound (10%), and calcium-, 
magnesium- and sodium compounds (1%) (Escobar et al., 2013). If 
urine pH is >7.4, approximately 80% of total phosphate concentration is 
in the divalent form (HPO42–), while 20% will be in the monovalent 
form (H2PO2–) (Kartamyisheva et al., 2011). Usually, about 90% of 
phosphate in the glomerular filtrate is reabsorbed in the proximal tubule, 
and 80% reabsorbed proximally (Bastepe & Jüpper 2008; Natochin, 
2008; Escobar et al., 2013). The currently known main regulators of 
phosphate homeostasis include parathyroid hormone (PTH) and 
vitamin D3 (calcitriol) (Escobar et al., 2013) and leads to a higher 
plasma phosphorus concentration (Baroncelli et al., 2012).  
Calcitriol or biologically active form of vitamin D3 stimulates phos-
phate reabsorption. Phosphatonins include fibroblast growth factor 23, 
frizzled-related protein-4 and phosphoglycoprotein extracellular matrix. 
Fibroblast growth factor-23 (FGF-23) is a 26-kDa protein activating the 
specific cell surface receptors(FGFRs) (Perwad & Portale, 2011).  
The ENPP1 (173335), PHEX (300550), DMP1 (600980) and FGF23 
genes stimulate the elevation of fibroblast growth factor 23 (FGF-23). 
The FGF-23 gene is located on chromosome 12p13.3. Fibroblast growth 
factor 23 (FGF-23) is the gene identified as causative for autosomal domi-
nant hypophosphatemia rickets (Bai et al., 2004; Ben-Dov et al., 2007).  
The biological activity and physiological role of FGF-23 have 
recently been clarified. Several animal models (mice with excess FGF-23 
activity as a result of in vivo forced overexpression) exhibit hypophos-
phatemia and increased P excretion of 1.25-dihydroxyvitamin D (Sitara 
et al., 2004, Shimada et al., 2004a; Shimada et al., 2004b). FGF-23 
deficient mice are characterized by a severe aging-like phenotype 
associated with ectopic calcifications organ atrophy, and osteomalacia. 
Mice lacking FGF-23 were characterized by severe vascular- and soft 
tissue calcification (Kuro-o et al., 1997). Needless to mention that 
extensive vascular and soft tissue calcification in both FGF-23 and 
klotho ablated mice are associated with severe hyperphosphatemia, and 
increased serum level of hydroxyvitamin D. The FGF-23 biology was 
studied on mouse models treated with recombinant FGF-23 or 
overexpression of FGF-23. FGF-23 suppresses the expression of the 
types IIa and IIc sodium-phosphate cotransporters on the apical 
membrane of renal proximal tubular cells, thus inducing phosphaturia 
(Shimada et al., 2005). The phosphatidic action of FGF-23 is not 
expressed in the absence of sodium-hydrogen exchanger regulatory 
factor-1 (NHERF-1) and increases in the presence of parathyroid 
hormone (PTH). In addition, FGF-23 suppresses the formation of 
1,25(OH)2D, suppressing 1-alpha-hydroxylase (CYP27B1), which con-
verts 25-hydroxyvitamin D [25(OH)D] to 1,25(OH)2D and stimulates 
the formation 24-hydroxylase (CYP24), which converts 1,25(OH)2D 
into inactive metabolites in the proximal tubule of the kidneys. In ad-
dition, FGF-23 impairs the production of renal 1,25-dihydroxyvitamin 
D [1,25(OH)2D] by inhibiting the expression of CYP27B1, the enzyme 
that converts 25-(OH)D to inactive metabolites in the proximal tubule. 
FGF23 also reduces the expression of interstitial sodium-phosphate 
conveyor NPT2b (Saito et al., 2003), reducing the intestinal phosphate 
absorption.  
FGF-23 acts directly on the parathyroid gland to inhibit PTH syn-
thesis and secretion. It has been shown that FGF-23 activates the 
mitogen-activated protein kinase pathway leading to a decrease in 
parathyroid hormone (PTH) secretion both in vivo rats and in vitro 
shingles (Ben-Dov et al., 2007). FGF-23 has also been shown to increa-
se expression of parathyroid 1-alpha-hydroxylase (Krajisnik et al., 2007), 
which converts 25-hydroxyvitamin D [25(OH)D] to 1,25(OH)2D.  
FGF-23 secretion is regulated by local bone-derived factors, such as 
phosphate-regulating gene with homologies to endopeptidases and den-
tin matrix protein-1 (Lorenz-Depiereux et al., 2006a; Lorenz-Depiereux 
et al., 2006b). 1,25(OH)2D affects FGF-23 secretion both in vivo and in vitro 
through the activation of FGF-23 mediated vitamin D (Liu et al., 2006). 
1. Factors decreasing phosphate reabsorption:  
– parathyroid hormone;  
– atrial natriuretic peptide;  
– glucocorticoids;  
– dopamine.  
Phosphauric factors:  
– fibroblasts 23 growth factor;  
– fibroblasts 7 growth factor;  
– matrix extracellular phosphoglycoprotein (MEPE);  
– other.  
2. Factors increasing phosphate reabsorption:  
– parathyroidectomy;  
– 11α25(OH)2D3;  
– growth hormone;  
– insulin-like growth factor;  
– food regulation;  
– acute (minutes, hours);  
– chronic (hours, days);  
– several system factors.  
X-linked recessive hypophosphatemia rickets (Dent’s disease) 
(ОМІМ 300554)  
The disease is caused mainly by mutations in the CLCN5 gene 
located on chromosome Xp11.22.  
X-linked recessive hypophosphatemia rickets is a form of X-linked 
hypercalciuric nephrolithiasis, which comprises a group of disorders 
characterized by proximal renal tubular reabsorptive failure, hypercalci-
uria, nephrocalcinosis, and renal insufficiency.  
Clinical features: rickets or osteomalacia, hypercalciuria, hypo-
phosphatemia and proteinuria in children. Progressive calcification and 
renal failure in adult patients (Gambaro et al., 2004). Clinically, it may 
show bone pain, fatigue, muscle weakness, and repeated bone fractures. 
Symptoms are related to bone pain, fatigue, muscle weakness and 
recurrent bone fractures.  
Autosomal dominant hypophosphatemia rickets (ОМІМ 193100) 
Autosomal dominant hypophosphatemia rickets (ADHR) results 
from activating mutations in a fibroblast growth factor 23 (FGF-23) 
gene in chromosome 12p13 encoding a phosphate-regulating hormone 
(Sun et al., 2012; Wöhrle et al., 2013).  
Small amounts of the gene originate in the brain, thymus, small 
intestine, heart, liver, lymph nodes, thyroid-shaped and pterygoid glands, 
bone marrow and in large quantities in tumors with oncogenic osteoma-
lacia. No expression in the bones. Elevated levels of FGF-23 are asso-
ciated with inhibition of reabsorption of phosphates in the renal tubule 
and hypophosphatemia. FGF-23 can physiologically function as a 
locally active factor secreted in excessive amounts in conditions of 
pathology, and may cause renal phosphate loss.  
Less than 100 cases have been described.  
Clinical manifestations depend on the age of onset and on the 
severity of hypophosphatemia.  
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Clinical features: ADHR shows incomplete penetrance and variab-
le age at onset (childhood to adult). Phosphate excretion can be evalua-
ted by measuring the maximum tubular reabsorption per glomerular 
filtration rate.  
Laboratory diagnosis: It is characterized by severe hypophosphat-
emia arising from a defect in the renal reabsorption of filtered inorganic 
phosphorus (Pi), elevated serum alkaline phosphatase activity and fibro-
blast growth factor 23 (FGF-23), inappropriately low-normal serum 
concentration of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] levels for 
the degree of prevailing hypophosphatemia (Econs et al., 1997).  
Treatment: aimed at improving growth, enhancing mineralization 
of bones, and preventing skeletal deformities caused by rickets. It con-
sists of daily oral administration of phosphate and calcitriol and is 
associated with frequent monitoring of calcium, alkaline phosphatase 
and parathyroid hormone, and phosphate serum concentrations, as well 
as urinary calcium and creatinine.  
Autosomal recessive hypophosphatemia rickets type 1 (ARHR1) 
(ОМІМ 241520) 
ARHR1 is caused by homozygous loss-of-function mutations in 
the DMP1 (Dentin matrix protein 1) gene in chromosome 4q22.  
Clinical features: Lower-extremity deformities. No response to vi-
tamin D therapy (vitamin D resistant rickets), high bone density. Back 
pain, restricted joint motion. Premature fusion of the skull bones. 
Deafness (aplasia of the vestibulocochlear nerve that results in ipsilateral 
congenital sensorineural hearing loss). Dental defects and early caries. It 
is accompanied by muscle weakness and pathologic fractures.  
Radiographic evaluation: early osteosclerosis and skull thickening, 
trabecular bone density in ribs (Feng et al., 2006; Lorenz-Depiereux 
et al., 2006a).  
Laboratory diagnosis: there are no symptoms of hypophosphatemia.  
Autosomal recessive hypophosphatemia rickets type 2 (ARHR2) 
(ОМІМ 613312)  
ARHR2 is caused by homozygous loss-of-function mutation in the 
ENPP1 gene in chromosome 6 (6q). Mutations in ENPP1 gene are also 
responsible for generalized arterial calcification of infancy.  
Clinical features: hypophosphatemia rickets, sometimes generali-
zed arterial calcification of infancy (Lorenz-Depiereux et al., 2010).  
Laboratory diagnosis: hypophosphatemia.  
X-linked, dominant, hypophosphatemia rickets (XLHR) (ОМІМ 
307800)  
Inactivating mutations in PHEX gene with homologies to endopepti-
dase on the X chromosome (Xp22) have been identified as a cause of 
XLHR. This endopeptidase is mainly expressed in bones and teeth, regula-
ting FGF-23 synthesis. The disease occurs as an X-linked dominant disor-
der with complete penetrance often complicated by variable expressivity.  
PHEX revealed possible alternative regulatory mechanisms for phos-
phate homeostasis, bone mineralization, and vitamin D metabolism. 
It controls sodium-dependent phosphate transport proteins in intestinal 
and renal proximal tubular epithelial cells. The genetic disorder is asso-
ciated with inability of the renal proximal tubule to reabsorb phosphate, 
which affects intestinal phosphate absorption. PHEX is primarily exp-
ressed in osteoblasts, odontoblasts, lung, ovary, parathyroid gland, brain 
and muscle. We found no correlation between the location or type of 
mutation and the disease severity.  
In XLHR osteoblast is likely to produce some inhibitor. Moreover, 
it was reported that cross-transplantation of kidneys in hyp-children 
results in transfer of the mutant phenotype. It can be associated with the 
primary defect in osteoblasts, as the correction of hyperphosphatemia 
and calcitriol in patients were observed low mineralization zones around 
osteolytic lacunae. XLH is the most frequent form of hypophosphat-
emia rickets, with a prevalence of 1/20.000. The disease affects both 
sexes. Patients with early onset disease have phosphate wasting, rickets, 
and lower extremity deformities in childhood.  
Characteristics heritable dental developmental anomalies: enamel 
hypoplasia, dentinogenesis imperfecta, enlarged dentinal tubules, lea-
ding to tooth abscess. Characteristic cranial base abnormalities: thicke-
ning of outer cortical table of frontal bone and slightly sunken median 
line between the eyes at the forehead. Osteoarthritis of the lower extre-
mities is developed in adults, osteophytes are formed and in some cases 
hearing loss may occur. Muscular weakness and hypotension are not 
observed. Other clinical manifestations, such as enthesopathy (calcify-
cation of ligaments and their attachment to bone), which is accompa-
nied by joint pain and joint mobility disorders (Baroncelli et al., 2012).  
Laboratory diagnosis: hypophosphatemia with low renal phosphate 
reabsorption, normal serum calcium values, normal or low vitamin D 
serum level (1,25(OH)2D3 or calcitriol), normal serum parathyroid hor-
mone levels and increased serum alkaline phosphatase activity.  
Therapy aimed at normalization of PHT levels with calcitrol supp-
lementation and calcitriol. Correction of vitamin D deficiency state is 
not required. Calcitriol supplementation may prevent secondary hyper-
parathyroidism resulting from increased phosphate intake (Gaucher 
et al., 2009).  
 
Conclusions  
 
Although the diagnosis of tubulopathy remains complex and requi-
res expensive laboratory equipment and specialist expertise; it can be 
diagnosed in children showing the following symptoms: impaired 
growth, vitamin D resistant rickets (lower limb deformities between 2 
and 3 years of age). In the evaluation of such patients urine analysis is 
commonly used (levels of calcium, phosphorus, pH, bicarbonate, 
sodium, potassium, glucose, creatinine, protein, amino acids), blood 
count (levels of creatinine, uric acid, alkaline phosphatase, glucose, pH 
and sodium, bicarbonate, potassium, chloride, calcium, phosphorus 
ions) and ultrasound of the kidneys to detect nephrocalcinosis. Determina-
tion of serum parathyroid hormone concentration, vitamin D metabolites, 
aldosterone and plasma renin activity, cysteine lymphocyte concentra-
tion (suspicion to diagnose cystinosis) and ophthalmologist examination 
may also be used as additional diagnostic methods. Despite the fact that 
most tubulopathies can be diagnosed clinically, molecular genetic 
studies are needed to clarify the type of inheritance and prognosis.  
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